Abstract
We wanted to present a picture of patients with schizophrenia receiving risperidone long-acting injection (RLAI) treatment in a real-world setting. This was a retrospective cohort study; 379 patients with schizophrenia were enrolled and treated with different kinds of antipsychotic agents at E-Da Hospital, and received a 12-month follow up. The patients were distributed into three groups: the all-oral antipsychotic, oral risperidone and RLAI groups. The antipsychotic agents and dosages they used were recorded. The rate of rehospitalization, length of hospital stay, emergency room visits and medical expenditures were assessed. The RLAI group had a significantly higher rate of hospitalization before enrolment (the all-oral antipsychotic group was 32.1%, the oral risperidone group, 35.9%, and the RLAI group, 88.4%, P < 0.0001). After a 1-year follow up, all three groups were similar in rehospitalization rates (the all-oral antipsychotic group was 28.9%, the oral risperidone group, 30.1%, and the RLAI group, 30.2%, P > 0.999), length of hospital stay and number of emergency room visits during follow up. The most commonly used oral antipsychotics were risperidone (0.5-7 mg/day), quetiapine (65-1200 mg/day), and olanzapine (2-25 mg/d...Continue Reading
References
May 9, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·J A Cramer, R Rosenheck
Jun 23, 2004·Lancet·Kim T Mueser, Susan R McGurk
Oct 12, 2004·Lancet·Brendan D Kelly, Larkin Feeney
Aug 5, 2005·The New England Journal of Medicine·Lars Osterberg, Terrence Blaschke
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Nov 4, 2005·The New England Journal of Medicine·Ronald J Campbell
Apr 7, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Lizheng ShiStephen R Marder
Apr 1, 2008·Lancet·René S KahnUNKNOWN EUFEST study group
May 16, 2008·Epidemiologic Reviews·John McGrathJoy Welham
Nov 18, 2008·Journal of Clinical Psychopharmacology·Jelle VehofHuibert Burger
Feb 5, 2009·The Journal of Clinical Psychiatry·Maxine X PatelAnthony S David
Sep 11, 2009·CNS Drugs·Kayvon SalimiJeffrey A Lieberman
Sep 15, 2009·Health and Quality of Life Outcomes·Alejandra Caqueo-UrízarClaudia Miranda-Castillo
Aug 6, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wolfgang GaebelEnrico Smeraldi
Oct 15, 2010·Journal of Psychopharmacology·Kahyee Hor, Mark Taylor
Jan 25, 2011·Schizophrenia Research·Claudia LeuchtStefan Leucht
Mar 3, 2011·The American Journal of Psychiatry·Jari TiihonenPasi Korhonen
Mar 4, 2011·The New England Journal of Medicine·Robert A RosenheckUNKNOWN CSP555 Research Group
Nov 30, 2011·Molecular Psychiatry·T KishimotoC U Correll
Jan 20, 2012·Patient Preference and Adherence·Miguel BernardoAntonio Ciudad
Mar 28, 2012·BMC Psychiatry·Tim LambertUNKNOWN e-STAR Research Group
Jun 16, 2012·The Journal of Clinical Psychiatry·Paul G BarnettUNKNOWN CSP 555 Research Group
Sep 12, 2012·Schizophrenia Research and Treatment·Christian AsseburgUlf Persson
Apr 3, 2013·Journal of Psychosocial Nursing and Mental Health Services·N Kirk Morton, Donna Zubek
Apr 17, 2013·Paediatric Drugs·Silvio Caccia
Aug 16, 2013·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Rahul ManchandaNicola Banks
Sep 10, 2013·Psychiatry Research·David Bin-Chia WuKenneth Kwing Chin Lee
Sep 11, 2013·BMC Psychiatry·Marie-Hélène LafeuilleMei Sheng Duh
Oct 23, 2013·Journal of Clinical Psychopharmacology·Po-Chung JuChao-Hsiun Tang
Oct 30, 2013·Therapeutic Advances in Psychopharmacology·Kyoko HigashiMarc De Hert
Nov 1, 2013·World Journal of Psychiatry·Francisco Javier AcostaCarlos J Rodríguez
Nov 16, 2013·The Journal of Clinical Psychiatry·Taishiro KishimotoChristoph U Correll
Jan 1, 2014·The Journal of Nervous and Mental Disease·Sarah M LeathermanUNKNOWN CSP 555 Investigators
Mar 7, 2014·Neuropsychiatric Disease and Treatment·Richard WilliamsAnnette Lam